Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 50Pancreatic Neoplasms 14Neoplasms 11Lung Neoplasms 11Neoplasm Metastasis 7Breast Neoplasms 6Brain Neoplasms 6Head and Neck Neoplasms 4Gliosarcoma 4Glioblastoma 4Carcinoma, Hepatocellular 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Neuroendocrine Tumors 3Colorectal Neoplasms 3Carcinoma, Squamous Cell 3Prostatic Neoplasms 2Oligodendroglioma 2Non-Squamous Non-Small Cell Lung Cancer 2Glioma 2Familial ependymoma 2Esophageal Neoplasms 2Ependymoma 2Carcinoma, Renal Cell 2Carcinoma 2Carcinoid Tumor 2Astrocytoma 2Urinary Bladder Neoplasms 1Thrombocytosis 1Thoracic Neoplasms 1

Interventions

Letrozole 1Goserelin 1Erlotinib Hydrochloride 13-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Hormone-sensitive Metastatic Breast Cancer × Erlotinib Hydrochloride × Clear all
NCT01205685 2012-09-11

Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

Vanderbilt-Ingram Cancer Center

Phase 2 Terminated
11 enrolled 9 charts
Breast

Hormone-sensitive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡